These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1444 related items for PubMed ID: 26491824

  • 1. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G, Cappelli V, Di Sabatino A, Massaro MG, De Leo V.
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [Abstract] [Full Text] [Related]

  • 2. [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women].
    Musacchio MC, Cappelli V, Di Sabatino A, Morgante G, De Leo V.
    Minerva Ginecol; 2013 Feb; 65(1):89-97. PubMed ID: 23412023
    [Abstract] [Full Text] [Related]

  • 3. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
    Cappelli V, Di Sabatino A, Musacchio MC, De Leo V.
    Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
    [Abstract] [Full Text] [Related]

  • 4. Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
    Stracquadanio M, Ciotta L, Palumbo MA.
    Gynecol Endocrinol; 2018 Jun; 34(6):495-501. PubMed ID: 29265900
    [Abstract] [Full Text] [Related]

  • 5. Myo-inositol vs. D-chiro inositol in PCOS treatment.
    Formuso C, Stracquadanio M, Ciotta L.
    Minerva Ginecol; 2015 Aug; 67(4):321-5. PubMed ID: 25670222
    [Abstract] [Full Text] [Related]

  • 6. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
    De Cicco S, Immediata V, Romualdi D, Policola C, Tropea A, Di Florio C, Tagliaferri V, Scarinci E, Della Casa S, Lanzone A, Apa R.
    Gynecol Endocrinol; 2017 Sep; 33(9):698-701. PubMed ID: 28434274
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
    Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A.
    Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
    [Abstract] [Full Text] [Related]

  • 8. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
    Pizzo A, Laganà AS, Barbaro L.
    Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
    [Abstract] [Full Text] [Related]

  • 9. Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome.
    Fruzzetti F, Fidecicchi T, Palla G, Gambacciani M.
    Gynecol Endocrinol; 2020 Feb; 36(2):152-155. PubMed ID: 31317814
    [Abstract] [Full Text] [Related]

  • 10. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T, Dehghan-Kooshkghazi M.
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic approach for metabolic disorders and infertility in women with PCOS.
    Morgante G, Massaro MG, Di Sabatino A, Cappelli V, De Leo V.
    Gynecol Endocrinol; 2018 Jan; 34(1):4-9. PubMed ID: 28850273
    [Abstract] [Full Text] [Related]

  • 12. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
    Minozzi M, Nordio M, Pajalich R.
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
    [Abstract] [Full Text] [Related]

  • 13. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
    Genazzani AD, Prati A, Marchini F, Petrillo T, Napolitano A, Simoncini T.
    Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
    [Abstract] [Full Text] [Related]

  • 14. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
    Unfer V, Porcaro G.
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
    Zhao H, Xing C, Zhang J, He B.
    Reprod Health; 2021 Aug 18; 18(1):171. PubMed ID: 34407851
    [Abstract] [Full Text] [Related]

  • 16. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
    Fruzzetti F, Capozzi A, Canu A, Lello S.
    Gynecol Endocrinol; 2019 Jun 18; 35(6):506-510. PubMed ID: 30612488
    [Abstract] [Full Text] [Related]

  • 17. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
    Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A.
    Gynecol Endocrinol; 2017 Jan 18; 33(1):39-42. PubMed ID: 27808588
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study.
    Advani K, Batra M, Tajpuriya S, Gupta R, Saraswat A, Nagar HD, Makwana L, Kshirsagar S, Kaul P, Ghosh AK, Pradhan S, Mehta A, Jaiswal A, Nakhate KT, Kamdi S.
    J Obstet Gynaecol; 2020 Jan 18; 40(1):96-101. PubMed ID: 31339394
    [Abstract] [Full Text] [Related]

  • 19. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
    Schmidt TH, Khanijow K, Cedars MI, Huddleston H, Pasch L, Wang ET, Lee J, Zane LT, Shinkai K.
    JAMA Dermatol; 2016 Apr 18; 152(4):391-8. PubMed ID: 26720591
    [Abstract] [Full Text] [Related]

  • 20. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H, Tanir HM, Yildiz Z.
    Arch Gynecol Obstet; 2006 Jul 18; 274(4):227-32. PubMed ID: 16691383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.